- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02527174
A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia (VIAC)
A Phase I Study of Volasertib Combined With Standard Induction Chemotherapy for Previously Untreated Patients With Acute Myeloid Leukemia (VIAC)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Main inclusion criteria:
- AML, any subtype except acute promyelocytic leukemia (APL)
At least one of the following features:
i. Age 18-75 with adverse risk cytogenetics ii. Age 18-75 with antecedent myelodysplastic syndrome (MDS) or myeloproliferative disorder (MPD), or therapy-related AML iii. Age 60-75, regardless of risk category
- No prior therapy for AML other than hydroxyurea
- Judged by treating physician to be medically fit for induction chemotherapy
- Eastern Cooperative Oncology Group (ECOG) performance status score 0-2
- Normal left ventricular ejection fraction
Subjects will receive induction chemotherapy consisting of idarubicin 12 mg/m2 on Days 1-3 plus cytarabine 200 mg/m2 (age 18-59) or 100 mg/m2 (age 60-75) as a continuous IV infusion x 7 days. Volasertib will be administered on day 4 in a dose-escalation schedule, using a standard 3+3 dose escalation design, over 3 dose levels. Once the MTD has been determined, an additional dose expansion cohort will be accrued.
Study Type
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 4N2
- Tom Baker Cancer Centre
-
Edmonton, Alberta, Canada, T6G 2G3
- University of Alberta Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- AML, any World Health Organization (WHO) subtype except APL, either de novo or secondary; extramedullary AML (i.e. granulocytic sarcoma) is permitted.
At least one of the following features:
Age 18-75 with adverse risk cytogenetics, including:
- Complete or partial deletion of chromosome 5 or 7
- Complex karyotype, defined as > 3 abnormalities, excluding t(15;17). t(8;21) or inv(16) or variant
- 11q23 abnormality
- Inv(3)(q21;q26) or variant
- t(6;9)
- abn(17p)
- Age 18-75 with secondary AML, defined as arising from an antecedent myelodysplastic syndrome (MDS) or myeloproliferative disorder (MPD), or therapy-related AML
- Age 60-75, regardless of risk category
- No prior therapy for AML other than hydroxyurea (allowed for up to 28 days). Prior therapy for MDS, MPD or other malignancy is allowed.
- Judged by treating physician to be medically fit for induction chemotherapy
- ECOG performance status score 0-2.
- Left ventricular ejection fraction (LVEF) within normal limits, by myocardial multigated scan (MUGA) or echocardiogram.
- Signed and dated written informed consent prior to admission
Exclusion Criteria:
- Prior anthracycline exposure equivalent to > 300 mg/m2 doxorubicin.
- Prior chemotherapy or radiotherapy within previous four weeks except for hydroxyurea.
- Prior treatment with volasertib or any other Polo-like kinase inhibitor
- Known hypersensitivity to the trial drug
- Serum creatinine > 1.5 times (1.5x) upper limit of normal (ULN) or creatinine clearance (CLcr) < 30 ml/min (estimated creatinine clearance by the Cockcroft-Gault (C-G) equation
- Serum bilirubin > 1.5x ULN, or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3x ULN
- Persistence of clinically relevant therapy related toxicity from previous anti-cancer therapy
- Active central nervous system leukemia (no lumbar puncture required; clinical judgement is sufficient)
- Treatment with other investigational drugs or treatment in another clinical trial within the past 4 weeks before start of therapy or concomitantly with the trial
- Significant cardiovascular diseases (i.e. uncontrolled hypertension, unstable angina, history of infarction within the past 12 months prior to start of study treatment, congestive heart failure (> New York Heart Association-II), serious cardiac arrhythmia, pericardial effusion)
- QTcF prolongation > 470 ms or QT prolongation deemed clinically relevant by the investigator (e.g., congenital long QT syndrome).The QTcF will be calculated as the mean of the 3 ECGs taken at screening.
- Other concurrent malignancy requiring active therapy (except hormonal therapy for prostate or breast cancer).
- Severe uncontrolled infection. Controlled infection on antibiotics is permitted.
- Active or chronic hepatitis C and/or B infection
- Known HIV infection
- Serious illness or concomitant non-oncological disease such as neurologic, psychiatric, infectious disease or active ulcers (gastro-intestinal tract, skin) or laboratory abnormality that may increase the risk associated with study participation or study drug administration and in the judgment of the investigator would make the patient inappropriate for entry into the study.
- Patients who are sexually active and unwilling to use a medically acceptable method of contraception (e.g. such as implants, injectables, combined oral contraceptives, some intrauterine devices or vasectomized partner for participating females, condoms for participating males) during the trial and for at least six months after end of active therapy on study.
- Pregnancy or breast feeding, female patients must have a negative pregnancy test prior to commencing study treatment.
- Psychological, familial or sociological factors potentially hampering compliance with the study protocol and follow-up schedule
- Known or suspected active alcohol or drug abuse
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Study treatment arm
Will receive volasertib combined with idarubicin plus cytarabine in a 3+7 schedule as induction chemotherapy. Volasertib dose will be given on day 4 in a dose escalation schedule over 3 dose levels (140 mg/m2, 170 mg/m2, 200 mg/m2) in successive cohorts. Non-hematologic toxicity will be determined using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 criteria for adverse events. Hematologic toxicity will be determined by days to absolute neutrophil count (ANC) and platelet recovery. |
Addition of single dose of volasertib intravenously (IV) on Day 4 of treatment protocol.
Other Names:
Given IV daily on Days 1-3 of treatment protocol.
Given IV daily as 24-hour continuous infusion on Day 1-7 of treatment protocol.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Toxicity profile
Time Frame: Participants will be followed for duration of induction cycle (expected time 28-35 days) for toxicity.
|
Non-hematologic toxicities will be assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.
Hematologic toxicities will be assessed by determining number of days to neutrophil (ANC) recovery to >0.5 x10(9)/L or platelet recovery to >20 x10(9)/L.
|
Participants will be followed for duration of induction cycle (expected time 28-35 days) for toxicity.
|
Dose-limiting toxicity (DLT)
Time Frame: Participants will be followed for duration of induction cycle (expected time 28-35 days) for DLT assessment.
|
DLT is defined as grade 3-4 non-hematologic toxicity (except grade 3 nausea, vomiting, mucositis or creatinine elevation due to tumor lysis syndrome, and grade 3-4 neutropenic infections and electrolyte abnormalities) using CTCAE version 4.0.Hematologic DLT is defined as ANC recovery to >0.5 x10(9)/L or platelet recovery to >20 x10(9)/L of > 42 days.
|
Participants will be followed for duration of induction cycle (expected time 28-35 days) for DLT assessment.
|
Maximum tolerated dose (MTD)
Time Frame: Determined after completion of dose-escalation phase of study, which will take approx. 12-15 months.
|
MTD is defined as maximum dose of volasertib associated with < 2/6 DLTs at a given dose level.
|
Determined after completion of dose-escalation phase of study, which will take approx. 12-15 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete response rate of regimen
Time Frame: Responses will be determined at hematologic recovery (Day 28 or greater, up to Day 60).
|
Complete response (CR) defined as <5% marrow blasts with ANC > 1.0 x10(9)/L and platelets >100 x 10(9)/L, with no extramedullary disease.
CRi defined as same, but ANC <1.0 and/or platelets <100.
|
Responses will be determined at hematologic recovery (Day 28 or greater, up to Day 60).
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Joseph Brandwein, MD, University of Alberta
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Bone Marrow Diseases
- Hematologic Diseases
- Myeloproliferative Disorders
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Leukemia, Myelomonocytic, Acute
- Leukemia, Monocytic, Acute
- Leukemia, Megakaryoblastic, Acute
- Leukemia, Erythroblastic, Acute
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antibiotics, Antineoplastic
- Cytarabine
- Idarubicin
Other Study ID Numbers
- 1230-37
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leukemia, Myeloid, Acute
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Jacqueline Garcia, MDEli Lilly and CompanyCompletedCombination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaRelapsed Adult Acute Myeloid Leukemia | Refractory Adult Acute Myeloid LeukemiaUnited States
-
University of NebraskaNational Cancer Institute (NCI)Active, not recruitingSecondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Adult Acute Myeloid LeukemiaUnited States
Clinical Trials on Volasertib
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompletedNeoplasms | LeukemiaGermany, France, Italy, Belgium, Czechia
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Anne Beaven, MDBoehringer Ingelheim; National Comprehensive Cancer NetworkWithdrawn
-
Boehringer IngelheimWithdrawn
-
Boehringer IngelheimCompletedMyelodysplastic Syndromes | Leukemia, Myelomonocytic, ChronicJapan
-
Yale UniversitySidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Massey Cancer CenterWithdrawnLymphoma | Relapsed and Refractory Aggressive B- and T-cell LymphomasUnited States
-
Boehringer IngelheimTerminatedMyelodysplastic Syndromes | Leukemia, Myelomonocytic, ChronicFrance, Germany
-
Boehringer IngelheimTerminatedMyelodysplastic SyndromesJapan